Biomea Fusion (BMEA) Cash & Equivalents (2020 - 2026)

Biomea Fusion has disclosed Cash & Equivalents across 7 years of filings, most recently posting $34.8 million for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 38.06% year-over-year to $34.8 million; the TTM figure through Jun 2026 stood at $34.8 million (down 38.06% YoY), while the FY2025 annual figure was $55.8 million, down 4.84% from the prior year.
• Cash & Equivalents came in at $34.8 million for Q2 2026 at Biomea Fusion, down from $44.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $223.3 million in Q2 2023 to a low of $34.8 million in Q2 2026.
• Average Cash & Equivalents over 5 years is $106.5 million, with a median of $100.3 million recorded in 2022.
• Year-over-year, Cash & Equivalents surged 719.42% in 2022 and plunged 75.32% in 2025.
• Over 5 years, Cash & Equivalents stood at $112.2 million in 2022, then surged by 57.89% to $177.2 million in 2023, then plunged by 66.91% to $58.6 million in 2024, then decreased by 4.84% to $55.8 million in 2025, then slumped by 37.6% to $34.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $34.8 million in Q2 2026, $44.7 million in Q1 2026, and $55.8 million in Q4 2025.